METTL9 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | <1E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
3.00469982228435E-10 |
Normal-vs-Stage2 |
1.556200E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
9.629300E-04 |
Stage1-vs-Stage2 |
8.239600E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.554400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
9.066600E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.67563748934663E-14 |
Normal-vs-AfricanAmerican |
1.342830E-01 |
Normal-vs-Asian |
8.835500E-03 |
Caucasian-vs-AfricanAmerican |
6.091000E-01 |
Caucasian-vs-Asian |
3.842200E-01 |
AfricanAmerican-vs-Asian |
8.087000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
4.20490000041518E-07 |
Normal-vs-Female |
9.96747129278219E-12 |
Male-vs-Female |
7.338000E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.6827899999905E-05 |
Normal-vs-Extreme_Weight |
1.74299999988747E-07 |
Normal-vs-Obese |
4.030500E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
6.149400E-01 |
Normal_Weight-vs-Obese |
5.997800E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
3.383600E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.280990E-01 |
Normal-vs-Age(41-60Yrs) |
2.09929999999137E-05 |
Normal-vs-Age(61-80Yrs) |
3.76376707578174E-12 |
Normal-vs-Age(81-100Yrs) |
4.655800E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.039000E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.745400E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.673600E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.761800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.492600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.215500E-02 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
1.681240E-01 |
Normal-vs-Grade 3 |
3.598400E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
3.592800E-01 |
Grade 2-vs-Grade 4 |
1.681240E-01 |
Grade 3-vs-Grade 4 |
3.598400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.65223390524716E-12 |
Normal-vs-N1 |
4.319200E-03 |
N0-vs-N1 |
2.064000E-01 |
|
|